Brookstone Capital Management Acquires 139 Shares of Becton, Dickinson and Company (NYSE:BDX)

Brookstone Capital Management grew its holdings in Becton, Dickinson and Company (NYSE:BDX) by 1.2% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 11,725 shares of the medical instruments supplier’s stock after purchasing an additional 139 shares during the quarter. Brookstone Capital Management’s holdings in Becton, Dickinson and Company were worth $2,901,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of BDX. Livelsberger Financial Advisory purchased a new position in shares of Becton, Dickinson and Company in the 4th quarter worth approximately $27,000. OLD Point Trust & Financial Services N A purchased a new position in shares of Becton, Dickinson and Company in the 4th quarter worth approximately $29,000. DiNuzzo Private Wealth Inc. purchased a new position in shares of Becton, Dickinson and Company in the 4th quarter worth approximately $30,000. Scarborough Advisors LLC purchased a new position in shares of Becton, Dickinson and Company in the 4th quarter worth approximately $32,000. Finally, Fortitude Family Office LLC purchased a new position in shares of Becton, Dickinson and Company in the 4th quarter worth approximately $35,000. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Performance

Shares of NYSE BDX opened at $230.84 on Friday. The company has a current ratio of 1.41, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62. Becton, Dickinson and Company has a 12 month low of $224.00 and a 12 month high of $287.32. The company has a 50 day simple moving average of $234.42 and a two-hundred day simple moving average of $237.88. The stock has a market cap of $66.72 billion, a price-to-earnings ratio of 50.85, a PEG ratio of 2.05 and a beta of 0.44.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, May 2nd. The medical instruments supplier reported $3.17 EPS for the quarter, beating the consensus estimate of $2.97 by $0.20. Becton, Dickinson and Company had a net margin of 6.76% and a return on equity of 13.90%. The business had revenue of $5.05 billion during the quarter, compared to analysts’ expectations of $5.04 billion. During the same period in the previous year, the business posted $2.86 EPS. The business’s quarterly revenue was up 4.6% compared to the same quarter last year. As a group, analysts predict that Becton, Dickinson and Company will post 13.04 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 28th. Shareholders of record on Monday, June 10th will be paid a dividend of $0.95 per share. This represents a $3.80 annualized dividend and a yield of 1.65%. The ex-dividend date of this dividend is Monday, June 10th. Becton, Dickinson and Company’s payout ratio is 83.70%.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, SVP Thomas J. Spoerel sold 300 shares of Becton, Dickinson and Company stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $239.31, for a total transaction of $71,793.00. Following the completion of the sale, the senior vice president now directly owns 1,976 shares in the company, valued at approximately $472,876.56. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, EVP Michael David Garrison sold 1,715 shares of the business’s stock in a transaction on Tuesday, April 30th. The shares were sold at an average price of $232.81, for a total value of $399,269.15. Following the completion of the transaction, the executive vice president now directly owns 5,381 shares in the company, valued at approximately $1,252,750.61. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Thomas J. Spoerel sold 300 shares of the business’s stock in a transaction on Monday, June 10th. The shares were sold at an average price of $239.31, for a total transaction of $71,793.00. Following the completion of the transaction, the senior vice president now owns 1,976 shares of the company’s stock, valued at $472,876.56. The disclosure for this sale can be found here. In the last ninety days, insiders sold 8,615 shares of company stock worth $2,033,381. Company insiders own 0.31% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on BDX. The Goldman Sachs Group began coverage on shares of Becton, Dickinson and Company in a research report on Thursday, May 30th. They issued a “buy” rating and a $274.00 price objective on the stock. StockNews.com downgraded shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Thursday. Finally, Barclays lifted their price objective on shares of Becton, Dickinson and Company from $305.00 to $312.00 and gave the stock an “overweight” rating in a research report on Monday, May 6th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $280.17.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.